<DOC>
	<DOCNO>NCT01760343</DOCNO>
	<brief_summary>A new formulation Berinert ( CSL830 ) investigate management hereditary angioedema ( HAE ) . The main aim study ass safety single 1500 IU dose new formulation Berinert . This study also look pharmacokinetics CSL830 relative Berinert currently market .</brief_summary>
	<brief_title>A Study Evaluate Safety Pharmacokinetics Two Formulations C1-esterase Inhibitor</brief_title>
	<detailed_description />
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas , Hereditary</mesh_term>
	<mesh_term>Hereditary Angioedema Types I II</mesh_term>
	<mesh_term>Complement C1 Inactivator Proteins</mesh_term>
	<mesh_term>Complement C1 Inhibitor Protein</mesh_term>
	<mesh_term>Complement C1s</mesh_term>
	<criteria>Healthy subject without clinically significant medical condition laboratory abnormality Male female subject age 18 45 year inclusive , time informed consent Nonsmokers Body mass index 18.0 29.0 kg/m2 inclusive Previous history clinically significant arterial venous thrombosis , current history clinically significant prothrombotic risk , clinically significant abnormality laboratory thrombotic screen screen visit . Known suspected hypersensitivity investigational medicinal product ( IMP ) , excipients IMP . Female subject start take change dose hormonal contraceptive regimen hormone replacement therapy ( ie , estrogen/progesterone contain product ) within 3 month screen visit . Alcohol , drug , medication abuse within one year study . Female subject childbearing potential ( eg , postmenopausal ) either use , willing use , medically reliable method contraception entire duration study , vasectomized partner , sexually abstinent entire duration study , surgically sterile . Participation another clinical study ( use another IMP ) within 30 day ( 5 time halflife , whichever long ) , , study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>